Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer worldwide and the third leading cause of cancer death worldwide. Alfa Cytology is a world leader in the development of cancer vaccines. With our extensive experience and advanced platform, we are confident we can provide the best vaccine development services for liver cancer.
The main risk factors for liver cancer are hepatitis B and C virus (HBV and HCV) infection. Non-viral causes include alcoholism and aflatoxin. HCC is the most common primary liver malignancy, accounting for approximately 6% of all newly diagnosed cancer cases globally. The overall prognosis for HCC patients is poor, with 5-6% survival at 5 years.
Cancer vaccines based on tumor-associated antigen (TAA) can initiate a powerful anti-tumor immune response through antigen-presenting cells such as dendritic cells (DC) and macrophages, showing great potential in cancer prevention and therapy. The number of commonly used liver cancer TAAs is limited and can be divided into the following categories.
| Cancer/Testicular (CT) Antigens |
|
| Widespread Overexpressed Antigens |
|
| Oncofetal Antigen |
|
Initiating or enhancing the body's immune response against cancer is the main goal of cancer immunization strategies. Suppression of T cells during tumor microenvironment homeostasis and reduced influx of T cells into tumor invasion reduce the effectiveness of some immunotherapies. The following table shows some commonly used vaccine types classified according to different standards.
Types of Vector
Types of Vaccine
Phase of Cancer
Nowadays, there are trials of immunotherapy based on a variety of strategies, but the effective results are very limited. To improve these conditions, Alfa Cytology provides a variety of services related to liver cancer vaccine development by addressing specific constraints.
To develop a more effective liver cancer vaccine, it is necessary to identify new and more specific TAAs, tumor-specific antigens (TSAs), or epitopes designed to induce specific CD4+ and CD8+ T cell activation. To achieve this, Alfa Cytology provides the following related antigen identification services.
| In Silico Prediction | TAA/TSA Identification |
|---|---|
|
|
|
|
|
|
Identification of novel specific tumor epitopes for liver cancer
Peptides
Proteins
DNA
RNA
DC
...
Vaccine strategies
Combinatorial strategies
Adjuvants
Delivery Systems
Improved efficacy of liver cancer vaccine
Developing innovative and more effective cancer vaccines remains at the forefront of cancer immunotherapy. Personalized and combination therapies will play a crucial role in enhancing the efficacy of cancer vaccines. Alfa Cytology is committed to the research and development of cancer vaccines, from the discovery of cancer antigens, and the development of different types of vaccines, to vaccine research for different cancer types, providing one-stop services. If you are interested in our service, please contact us.